Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy AVROBIO stock | $5.58

Learn how to easily invest in AVROBIO stock.

AVROBIO Inc is a biotechnology business based in the US. AVROBIO shares (AVRO) are listed on the NASDAQ and all prices are listed in US Dollars. AVROBIO employs 121 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in AVROBIO

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AVRO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

AVROBIO stock price (NASDAQ: AVRO)

Use our graph to track the performance of AVRO stocks over time.

AVROBIO shares at a glance

Information last updated 2021-10-16.
Latest market close$5.58
52-week range$5.23 - $20.07
50-day moving average $6.02
200-day moving average $8.19
Wall St. target price$23.44
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.10

Buy AVROBIO shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AVROBIO stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AVROBIO price performance over time

Historical closes compared with the close of $5.58 from 2021-10-20

1 week (2021-10-12) -1.41%
1 month (2021-09-22) -8.67%
3 months (2021-07-22) -28.09%
6 months (2021-04-22) -50.75%
1 year (2020-10-21) -64.07%
2 years (2019-10-21) -60.73%
3 years (2018-10-19) 27.44
5 years (2016-10-18) N/A

AVROBIO financials

Gross profit TTM $0
Return on assets TTM -31.16%
Return on equity TTM -53.47%
Profit margin 0%
Book value $5.07
Market capitalisation $253 million

TTM: trailing 12 months

Shorting AVROBIO shares

There are currently 2.3 million AVROBIO shares held short by investors – that's known as AVROBIO's "short interest". This figure is 32.8% down from 3.4 million last month.

There are a few different ways that this level of interest in shorting AVROBIO shares can be evaluated.

AVROBIO's "short interest ratio" (SIR)

AVROBIO's "short interest ratio" (SIR) is the quantity of AVROBIO shares currently shorted divided by the average quantity of AVROBIO shares traded daily (recently around 408267.44186047). AVROBIO's SIR currently stands at 5.59. In other words for every 100,000 AVROBIO shares traded daily on the market, roughly 5590 shares are currently held short.

However AVROBIO's short interest can also be evaluated against the total number of AVROBIO shares, or, against the total number of tradable AVROBIO shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AVROBIO's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 AVROBIO shares in existence, roughly 50 shares are currently held short) or 0.0703% of the tradable shares (for every 100,000 tradable AVROBIO shares, roughly 70 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AVROBIO.

Find out more about how you can short AVROBIO stock.

AVROBIO share dividends

We're not expecting AVROBIO to pay a dividend over the next 12 months.

AVROBIO share price volatility

Over the last 12 months, AVROBIO's shares have ranged in value from as little as $5.23 up to $20.07. A popular way to gauge a stock's volatility is its "beta".

AVRO.US volatility(beta: 1.37)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVROBIO's is 1.3681. This would suggest that AVROBIO's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

AVROBIO overview

AVROBIO, Inc. , a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of AVROBIO is owned by insiders or institutions?
Currently 2.939% of AVROBIO shares are held by insiders and 92.354% by institutions.
How many people work for AVROBIO?
Latest data suggests 121 work at AVROBIO.
When does the fiscal year end for AVROBIO?
AVROBIO's fiscal year ends in December.
Where is AVROBIO based?
AVROBIO's address is: Building 300, Cambridge, MA, United States, 02139
What is AVROBIO's ISIN number?
AVROBIO's international securities identification number is: US05455M1009
What is AVROBIO's CUSIP number?
AVROBIO's Committee on Uniform Securities Identification Procedures number is: 05455M100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site